[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636778":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":34,"centralContacts":38,"locations":44,"responsibleParty":65,"collaborators":28,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":28,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":28,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":98,"whyStopped":28,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Weill Medical College of Cornell University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Exposure and Response Prevention Therapy","EXPERIMENTAL","Participants receive exposure and response prevention (ERP) therapy, an evidence-based form of cognitive behavioral therapy for obsessive-compulsive disorder. Participants also receive repeated clinical assessments and research MRI sessions. ERP consists of 14 weekly sessions of approximately 60 minutes each, followed by three scheduled monthly booster sessions and optional symptom-triggered booster sessions during the maintenance phase. ERP may be delivered in person or by HIPAA-compliant telehealth. Clinical assessments are used to measure OCD symptoms and related outcomes over time, and MRI sessions are used to evaluate brain connectivity.",[13,14,15],"Behavioral: Exposure and Response Prevention Therapy","Other: Clinical Assessments","Diagnostic Test: Research MRI Sessions",[17,24,29],{"type":18,"name":9,"description":19,"armGroupLabels":20,"otherNames":21},"BEHAVIORAL","Exposure and response prevention (ERP) is an evidence-based form of cognitive behavioral therapy for obsessive-compulsive disorder. ERP involves graded exposure to obsession-triggering cues while supporting participants in refraining from compulsive responses. In this study, participants receive 14 planned weekly ERP sessions of approximately 60 minutes each, followed by three scheduled monthly booster sessions and optional symptom-triggered booster sessions during the maintenance phase. ERP may be delivered in person or by HIPAA-compliant telehealth.",[9],[22,23],"Exposure and Response Prevention","ERP",{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"Clinical Assessments","Participants complete repeated clinical assessments according to the study schedule to evaluate obsessive-compulsive disorder symptom severity, symptom change, functioning, safety, and related clinical outcomes over time. Assessments may include clinician-administered ratings, participant-report measures, and other study outcome measures. These assessments are conducted for research and clinical monitoring purposes and are not intended as a therapeutic intervention.",[9],null,{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":28},"DIAGNOSTIC_TEST","Research MRI Sessions","Participants complete research magnetic resonance imaging sessions at scheduled study time points to acquire structural and functional MRI data, including functional MRI measures used to evaluate brain connectivity over time. Imaging sessions are used to examine changes in brain circuitry in relation to obsessive-compulsive disorder symptoms and treatment course. These sessions are conducted for research measurement purposes and are not intended to provide clinical diagnosis or treatment.",[9],[35],{"name":36,"affiliation":5,"role":37},"Conor Liston, MD, PhD","PRINCIPAL_INVESTIGATOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":28,"email":43},"Jihoon Kim, MD, MSc","CONTACT","862-414-3322","gmj9009@med.cornell.edu",[45],{"facility":46,"status":28,"city":47,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"NewYork-Presbyterian Hospital \u002F Weill Cornell Medicine","New York","10065","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-74.00597,40.71427,{"lat":55,"lon":54},[58,62,63],{"name":59,"role":41,"phone":60,"phoneExt":28,"email":61},"Andrei Gangal","212-746-3663","ang2050@med.cornell.edu",{"name":36,"role":37,"phone":28,"phoneExt":28,"email":28},{"name":40,"role":64,"phone":28,"phoneExt":28,"email":28},"SUB_INVESTIGATOR",{"type":66,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100636778","precision-brain-mapping-to-predict-and-track-response-to-exposure-and-response-prevention-therapy-in-youth-with-obsessive-compulsive-disorder-100636778",false,"NCT07570108","Precision Brain Mapping to Predict and Track Response to Exposure and Response Prevention Therapy in Youth With Obsessive-Compulsive Disorder","Precision Functional Mapping to Predict and Track ERP Response in Pediatric Obsessive-Compulsive Disorder: A Longitudinal fMRI Study","Inclusion Criteria:\n\n* Age 10 to 17 years at the time of initial consent. Participants who reach age 18 while enrolled may remain in the study after completing the adult re-consent process; no new participants age 18 years or older will be recruited.\n* DSM-5 diagnosis of obsessive-compulsive disorder, established through a clinical interview by a clinician.\n* Parent or guardian able to provide informed consent and participant able to provide assent.\n* Participant has sufficient English fluency to complete cognitive tasks and assessments. Parent or guardian English fluency is not required; interpreter support is available.\n\nExclusion Criteria:\n\n* History or current evidence of a significant neurological disorder, including but not limited to seizure disorder, stroke, or traumatic brain injury with loss of consciousness.\n* Any standard MRI contraindication identified during initial screening or on the MRI safety checklist, including but not limited to ferromagnetic implants, certain medical devices or metal fragments, severe claustrophobia, or pregnancy.\n* Pregnancy at screening or pregnancy identified during study participation.\n* Active suicidal ideation.\n* Any psychiatric condition that, in the investigator's judgment, would interfere with study participation or data interpretation, including but not limited to psychotic disorders, bipolar disorders, severe neurodevelopmental disorders, intellectual disability, severe eating disorders, or recent significant substance use disorders within the past 6 months. Stable psychiatric comorbidities, including anxiety disorders, depressive disorders, ADHD, or tic disorders, are permitted if OCD remains the primary diagnosis.\n* Any medical, psychiatric, or situational factor judged by the investigator as likely to compromise participant safety, adherence, or data integrity.","ALL","10 Years","17 Years",{"count":78,"type":79},30,"ESTIMATED","INTERVENTIONAL",[82],"NA","The goal of this clinical trial is to learn whether brain scan results can help predict and track changes in obsessive-compulsive disorder, or OCD, symptoms in children and teens ages 10 to 17 who receive Exposure and Response Prevention therapy, also called ERP. ERP is a type of therapy in which participants practice facing OCD-related fears while resisting rituals or compulsions.\n\nThe main question this study aims to answer is:\n\nCan each participant's pattern of brain connections, measured with functional MRI brain scans, help predict and track weekly changes in OCD symptoms during and after a 14-week course of ERP, including during planned monthly booster sessions and additional booster sessions offered if symptoms worsen?\n\nAll participants will receive ERP. There is no placebo and no comparison group.\n\nParticipants will:\n\n* Complete screening, consent or assent, interviews, questionnaires, and MRI safety checks\n* Receive 14 weekly ERP sessions\n* Complete OCD symptom assessments and functional MRI brain scans before, during, and after ERP\n* Receive planned monthly ERP booster sessions after the 14 weekly sessions\n* Receive additional brief ERP booster sessions if OCD symptoms worsen during follow-up\n* Take part for up to about 62 weeks",[85],"Obsessive-Compulsive Disorder",[87,88,89,90,91,23,92,93,94,95,96,97],"Obsessive-compulsive disorder","Pediatric obsessive-compulsive disorder","OCD","Pediatric OCD","Exposure and response prevention","Cognitive behavioral therapy","Functional magnetic resonance imaging","Resting-state functional connectivity","Precision functional mapping","Longitudinal neuroimaging","Treatment response biomarker","NOT_YET_RECRUITING","2026-04-29",{"date":101,"type":102},"2026-05-06","ACTUAL",{"date":104,"type":79},"2026-05",{"date":106,"type":79},"2031-08",{"name":5,"class":6},1]